Three randomized, multicenter, phase 2 studies demonstrated the efficacy and safety of omidenepag isopropyl as an alternative method to lower IOP, according to a study.
Omidenepag is a selective, non-prostaglandin, prostanoid E2 receptor 2 agonist that increases aqueous humor outflow through both the conventional and the uveoscleral pathways. In a previous phase 1 study, it was demonstrated to be effective and well tolerated.
Studies 1 and 2 were conducted in the United States, and study 3 was conducted in Japan. A total of 338 patients with open angle glaucoma or (Read more...)
Uncategorized